THE SURFCE MEMBRANES OF NORMAL AND CANCER CELLS

研究发现，UDP-半乳糖与GTP、Mn2+和 转化细胞的提取液导致几个快速形成 迁移产品。其中两款产品占主导地位，《极速巅峰2》 (Fp2)和《Fast Peak 4》(Fp4)。该反应是由芦荟提取物催化的。 Ras癌基因产物突变或升高的转化细胞 (K-ras、H-ras和N-ras)。在人类肿瘤细胞系中也发现了活性 (乳腺、肺、膀胱)、SV40转化细胞和化学转化 肝细胞。在各种对照细胞中未检测到该反应， 多发性瘤和Rous病毒转化的细胞和一些恶性细胞。 初步实验表明，该反应由一种提取物催化。 抗ras抗体可抑制KMSV转化的小鼠成纤维细胞 单抗。 我们的目标是：(A)获得足够的材料来建立这些结构 Fp2和fp4；(B)研究它们对细胞的影响和与 控制生长，以确定它们在恶性(和正常)中的作用 细胞，即FP衍生物是否参与正常的控制 生长和分化；(C)分离酶和因子 参与FP的合成；(D)确定反应的性质 以及fp2和fp4的代谢关系；(E)证实ras基因 产品是机制的一部分，并决定着RAS的作用 正常和恶性细胞中的蛋白质；和(F)确定其分布 正常组织和癌变组织中FP合成酶的表达。我们也 计划在以下方面完成正在进行的研究： 1)CMPNAN降解形成CMP丙酮酸。 2)对照细胞和转化细胞糖肽的比较。 3)环境和药物对其碳水化合物组成的影响 杂交瘤产生的免疫球蛋白和碳水化合物改变的后果 结构。

It has been found that incubation of UDP-galactose with GTP, Mn ions and extracts of transformed cells results in the formation of several rapidly migrating products. Two of these products are dominant, "Fast Peak 2" (FP2) and "Fast Peak 4" (FP4). The reaction is catalyzed by extracts of transformed cells with mutated or elevated levels of ras oncogene product (K-ras, H-ras and N-ras). Activity is also seen in human tumor cell lines (breast, lung, bladder), SV40-transformed cells and chemically transformed liver cells. The reaction is not detected in a variety of control cells, polyoma and Rous virus-transformed cells and some malignant cells. Preliminary experiments indicate that the reaction catalyzed by an extract of KMSV-transformed mouse fibroblasts can be inhibited by an anti-ras monoclonal antibody. Our aim is to: (a) obtain sufficient material to establish the structures of FP2 and FP4; (b) study their effects on cells and reactions related to growth control in order to establish their role in malignant (and normal) cells, i.e., whether the FP derivatives are involved in normal control of growth and differentiation; (c) fractionate the enzymes and factors involved in the synthesis of FP; (d) determine the nature of the reaction and the metabolic relation of FP2 and FP4; (e) establish that the ras gene product is a part of the mechanism and determine the action of the ras protein in normal and malignant cells; and (f) determine the distribution of the FP synthesizing enzymes in control and malignant tissues. We also plan to complete our studies in progress on: 1) the degradation of CMPNAN to form a putative CMPpyruvate. 2) comparison of glycopeptides of control and transformed cells. 3) the influence of environment and drugs on the carbohydrate component of IgG produced by hybridomas and the consequences of altered carbohydrate structure.